Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 55

1.

Investigating the duality of Inpp4b function in the cellular transformation of mouse fibroblasts.

Mangialardi EM, Chen K, Salmon B, Vacher J, Salmena L.

Oncotarget. 2019 Oct 29;10(59):6378-6390. doi: 10.18632/oncotarget.27293. eCollection 2019 Oct 29.

2.

Plasma RANKL levels are not associated with breast cancer risk in BRCA1 and BRCA2 mutation carriers.

Zaman T, Sun P, Narod SA, Salmena L, Kotsopoulos J.

Oncotarget. 2019 Mar 29;10(25):2475-2483. doi: 10.18632/oncotarget.26810. eCollection 2019 Mar 29.

3.

Serum osteoprotegerin levels and mammographic density among high-risk women.

Moran O, Zaman T, Eisen A, Demsky R, Blackmore K, Knight JA, Elser C, Ginsburg O, Zbuk K, Yaffe M, Narod SA, Salmena L, Kotsopoulos J.

Cancer Causes Control. 2018 Jun;29(6):507-517. doi: 10.1007/s10552-018-1035-y. Epub 2018 Apr 20.

PMID:
29679262
4.

SubID, a non-median dichotomization tool for heterogeneous populations, reveals the pan-cancer significance of INPP4B and its regulation by EVI1 in AML.

Dzneladze I, Woolley JF, Rossell C, Han Y, Rashid A, Jain M, Reimand J, Minden MD, Salmena L.

PLoS One. 2018 Feb 7;13(2):e0191510. doi: 10.1371/journal.pone.0191510. eCollection 2018. Erratum in: PLoS One. 2018 Mar 29;13(3):e0195417.

5.

microRNAs and Acute Myeloid Leukemia Chemoresistance: A Mechanistic Overview.

Gabra MM, Salmena L.

Front Oncol. 2017 Oct 30;7:255. doi: 10.3389/fonc.2017.00255. eCollection 2017. Review.

6.

Plasma osteoprotegerin and breast cancer risk in BRCA1 and BRCA2 mutation carriers.

Odén L, Akbari M, Zaman T, Singer CF, Sun P, Narod SA, Salmena L, Kotsopoulos J.

Oncotarget. 2016 Dec 27;7(52):86687-86694. doi: 10.18632/oncotarget.13417.

7.

Reduced BRCA1 transcript levels in freshly isolated blood leukocytes from BRCA1 mutation carriers is mutation specific.

Chehade R, Pettapiece-Phillips R, Salmena L, Kotlyar M, Jurisica I, Narod SA, Akbari MR, Kotsopoulos J.

Breast Cancer Res. 2016 Aug 17;18(1):87. doi: 10.1186/s13058-016-0739-8.

8.

Preface.

Salmena L, Stambolic V.

Methods Mol Biol. 2016;1388:v. No abstract available.

PMID:
27482589
9.

Measurement of PTEN by Flow Cytometry.

Woolley JF, Salmena L.

Methods Mol Biol. 2016;1388:39-51. doi: 10.1007/978-1-4939-3299-3_4.

PMID:
27033069
10.

PTEN: History of a Tumor Suppressor.

Salmena L.

Methods Mol Biol. 2016;1388:3-11. doi: 10.1007/978-1-4939-3299-3_1.

PMID:
27033066
11.

Uninterrupted Sedentary Behavior Downregulates BRCA1 Gene Expression.

Pettapiece-Phillips R, Kotlyar M, Chehade R, Salmena L, Narod SA, Akbari M, Jurisica I, Kotsopoulos J.

Cancer Prev Res (Phila). 2016 Jan;9(1):83-8. doi: 10.1158/1940-6207.CAPR-15-0291. Epub 2015 Nov 2.

12.

Targeting mitochondrial RNA polymerase in acute myeloid leukemia.

Bralha FN, Liyanage SU, Hurren R, Wang X, Son MH, Fung TA, Chingcuanco FB, Tung AY, Andreazza AC, Psarianos P, Schimmer AD, Salmena L, Laposa RR.

Oncotarget. 2015 Nov 10;6(35):37216-28. doi: 10.18632/oncotarget.6129.

13.

Prognostic value of INPP4B protein immunohistochemistry in ovarian cancer.

Salmena L, Shaw P, Fans I, McLaughlin, Rosen B, Risch H, Mitchell C, Sun P, Narod SA, Kotsopoulos J.

Eur J Gynaecol Oncol. 2015;36(3):260-7.

PMID:
26189250
14.

Phosphoinositide signaling in cancer: INPP4B Akt(s) out.

Woolley JF, Dzneladze I, Salmena L.

Trends Mol Med. 2015 Sep;21(9):530-2. doi: 10.1016/j.molmed.2015.06.006. Epub 2015 Jul 3.

PMID:
26150301
15.

In Vivo Role of INPP4B in Tumor and Metastasis Suppression through Regulation of PI3K-AKT Signaling at Endosomes.

Li Chew C, Lunardi A, Gulluni F, Ruan DT, Chen M, Salmena L, Nishino M, Papa A, Ng C, Fung J, Clohessy JG, Sasaki J, Sasaki T, Bronson RT, Hirsch E, Pandolfi PP.

Cancer Discov. 2015 Jul;5(7):740-51. doi: 10.1158/2159-8290.CD-14-1347. Epub 2015 Apr 16.

16.

INPP4B overexpression is associated with poor clinical outcome and therapy resistance in acute myeloid leukemia.

Dzneladze I, He R, Woolley JF, Son MH, Sharobim MH, Greenberg SA, Gabra M, Langlois C, Rashid A, Hakem A, Ibrahimova N, Arruda A, Löwenberg B, Valk PJ, Minden MD, Salmena L.

Leukemia. 2015 Jul;29(7):1485-95. doi: 10.1038/leu.2015.51. Epub 2015 Mar 4.

PMID:
25736236
17.

BRCA1 mRNA levels following a 4-6-week intervention with oral 3,3'-diindolylmethane.

Kotsopoulos J, Zhang S, Akbari M, Salmena L, Llacuachaqui M, Zeligs M, Sun P, Narod SA.

Br J Cancer. 2014 Sep 23;111(7):1269-74. doi: 10.1038/bjc.2014.391. Epub 2014 Jul 15.

18.

Pseudogene redux with new biological significance.

Salmena L.

Methods Mol Biol. 2014;1167:3-13. doi: 10.1007/978-1-4939-0835-6_1. Review.

PMID:
24823767
19.

Cancer-associated PTEN mutants act in a dominant-negative manner to suppress PTEN protein function.

Papa A, Wan L, Bonora M, Salmena L, Song MS, Hobbs RM, Lunardi A, Webster K, Ng C, Newton RH, Knoblauch N, Guarnerio J, Ito K, Turka LA, Beck AH, Pinton P, Bronson RT, Wei W, Pandolfi PP.

Cell. 2014 Apr 24;157(3):595-610. doi: 10.1016/j.cell.2014.03.027.

20.

A co-clinical approach identifies mechanisms and potential therapies for androgen deprivation resistance in prostate cancer.

Lunardi A, Ala U, Epping MT, Salmena L, Clohessy JG, Webster KA, Wang G, Mazzucchelli R, Bianconi M, Stack EC, Lis R, Patnaik A, Cantley LC, Bubley G, Cordon-Cardo C, Gerald WL, Montironi R, Signoretti S, Loda M, Nardella C, Pandolfi PP.

Nat Genet. 2013 Jul;45(7):747-55. doi: 10.1038/ng.2650. Epub 2013 Jun 2.

Supplemental Content

Loading ...
Support Center